clofibric acid has been researched along with Hyperlipoproteinemia in 35 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 7.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 7.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "Treatment with ciprofibrate is effective and safe treatment in patients with combined hyperlipoproteinaemia." | 6.69 | [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic]. ( Ceska, R; Haas, T; Kvasnicka, T; Soska, V; Vaverková, H, 2000) |
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 5.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "The study of the hypolipidemic efficiency, safety and tolerance of ciprofibrate (lipanor) in therapy of atherogenic hyperlipoproteinemia." | 5.08 | [Lipanor treatment of atherogenic hyperlipoproteinemia]. ( Arabidze, GG; Kukharchuk, VV; Susekov, AV; Tvorogova, MG, 1998) |
| "A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid)." | 5.05 | [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. ( Steger, W, 1980) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 3.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 3.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "Treatment with ciprofibrate is effective and safe treatment in patients with combined hyperlipoproteinaemia." | 2.69 | [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic]. ( Ceska, R; Haas, T; Kvasnicka, T; Soska, V; Vaverková, H, 2000) |
| "Both bezafibrate and EPL were tolerated well." | 2.65 | [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)]. ( Bruneder, H; Klein, HJ, 1981) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia." | 2.39 | Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. ( Bruckert, E; Turpin, G, 1996) |
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 1.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "Ciprofibrate is a phenoxyisobutyrate derivative with lipid-lowering effects in hyperlipoproteinaemia." | 1.27 | Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. ( Angelin, B; Einarsson, K; Leijd, B, 1984) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (80.00) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carvalho, AA | 1 |
| Lima, UW | 1 |
| Valiente, RA | 1 |
| Kaffarnik, H | 2 |
| Schneider, J | 2 |
| Schubotz, R | 2 |
| Zöfel, P | 2 |
| Hausmann, L | 1 |
| Goebel, KM | 1 |
| Słowińska, R | 1 |
| Bochenek, W | 1 |
| Unlot, J | 1 |
| Angelin, B | 1 |
| Einarsson, K | 1 |
| Leijd, B | 1 |
| Schatton, W | 2 |
| Schlierf, G | 1 |
| Fischer, H | 1 |
| Roche, A | 1 |
| Stiehl, A | 1 |
| Oster, P | 1 |
| Schellenberg, B | 1 |
| Vollmar, J | 2 |
| Prager, R | 1 |
| Schernthaner, G | 1 |
| Kostner, GM | 1 |
| Mühlhauser, I | 1 |
| Zechner, R | 1 |
| Dorda, W | 1 |
| Reuter, W | 2 |
| Hanefeld, M | 1 |
| Kemmer, C | 1 |
| Kadner, E | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Machalke, K | 1 |
| Djaja, S | 1 |
| Richter, E | 1 |
| Lageder, H | 1 |
| Dick, TB | 1 |
| Marples, J | 1 |
| Ledermann, HM | 1 |
| Whittington, J | 1 |
| von Bock und Polach, U | 1 |
| Wechsler, JG | 1 |
| Hutt, V | 1 |
| Klör, HU | 1 |
| Bode, G | 1 |
| Ditschuneit, H | 1 |
| Mertz, DP | 1 |
| Lang, PD | 1 |
| Honorato Pérez, J | 1 |
| Azanza Perea, JR | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Bruneder, H | 1 |
| Klein, HJ | 1 |
| Steger, W | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Domingo, AJ | 1 |
| Gutiérrez, JA | 1 |
| Menéndez, JA | 1 |
| Micó, L | 1 |
| Muñoz, M | 1 |
| de Oya, M | 1 |
| Schwartzkopff, W | 1 |
| Schilling, A | 1 |
| Turpin, G | 1 |
| Bruckert, E | 1 |
| Susekov, AV | 1 |
| Tvorogova, MG | 1 |
| Arabidze, GG | 1 |
| Kukharchuk, VV | 1 |
| Gajdos, M | 1 |
| Fedelesova, V | 1 |
| Mongiellova, V | 1 |
| Cibulova, L | 1 |
| Huttova, D | 1 |
| Polak, F | 1 |
| Krivosikova, Z | 1 |
| Ceska, R | 1 |
| Kvasnicka, T | 1 |
| Haas, T | 1 |
| Soska, V | 1 |
| Vaverková, H | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Haslauer, F | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Schulze, J | 1 |
| Julius, U | 1 |
| Leonhardt, W | 1 |
| Haller, H | 1 |
| Holm, E | 1 |
2 reviews available for clofibric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipoproteinemias; Hypol | 1996 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
11 trials available for clofibric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; | 1983 |
[Pharmacology and mechanism of action of etofibrate].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypoli | 1982 |
[The effect of bezafibrate on biliary lipids (author's transl)].
Topics: Adult; Bezafibrate; Bile; Clofibrate; Clofibric Acid; Drug Evaluation; Humans; Hyperlipoproteinemias | 1980 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Chole | 1982 |
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibr | 1982 |
[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; P | 1980 |
Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; C | 1981 |
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complicat | 1981 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations | 1980 |
[Lipanor treatment of atherogenic hyperlipoproteinemia].
Topics: Cholesterol; Clofibric Acid; Coronary Artery Disease; Disease Progression; Drug Administration Sched | 1998 |
[Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
Topics: Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Mid | 2000 |
22 other studies available for clofibric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
Statin and fibrate associated myopathy: study of eight patients.
Topics: Adult; Aged; Anticholesteremic Agents; Biopsy; Clofibric Acid; Creatine Kinase; Drug Therapy, Combin | 2004 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholesterol; Clofibrate; Clofibric Acid; Female; Fibric Aci | 1984 |
[Longterm therapy and etofibrate (author's transl)].
Topics: Anticholesteremic Agents; Blood Cell Count; Blood Glucose; Clofibrate; Clofibric Acid; Drug Administ | 1980 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man.
Topics: Adult; Aged; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; Microbodies; M | 1983 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
[Lowering lipids rapidly and permanently with etofibrate].
Topics: Cholestyramine Resin; Clofibrate; Clofibric Acid; Dextrothyroxine; Humans; Hyperlipoproteinemias; Li | 1982 |
[Bezafibrate in primary hyperlipidemias (author's transl)].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Hu | 1982 |
Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoprote | 1982 |
[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
Topics: Cholesterol; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Humans; Hyperlipoproteinemias; Lip | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
[Current treatment with clofibrate or clofibric acid (Regadrin)].
Topics: Cholelithiasis; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipoprot | 1982 |
[What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipo | 1982 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Topics: Adult; Aged; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type | 1980 |
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Hum | 1980 |
[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 1999 |
[Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Drug Combinations; Female; Humans; Hyperlipopr | 1979 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Metabolism kinetic characterization of hypertriglyceridemias in drug therapy variations].
Topics: Adult; Blood Glucose; Buformin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-Action P | 1987 |
[Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Dietary Fats; Female; Humans; Hyperlipoprotein | 1986 |